Metropolis Healthcare Ltd. posts 7% YoY growth in Revenue to Rs. 293 crores

 Below are the key highlights of the results for your reference.

• Patient visits increased by 22% on YoY basis to 3.3 Mn in Q3FY22
• No. of tests increased by 24% on YoY basis to 6.3 Mn in Q3FY22
• Home-Visits test services now covered in more than 100 locations
• Declared interim dividend of Rs. 8 per share

In INR Crs.	Q3FY22	Q3FY21
Revenue from Operations	293.1	274.7
EBIDTA (before CSR, ESOP & one-time acquisition cost)	80.5	90.2
EBIDTA margin (before CSR, ESOP & one-time acquisition cost)	27.5%	32.8%
Reported Profit After Tax	41.2	58.6
Reported PAT Margin (%)	14.1%	21.3%

 

 

 

 

 

 

 

 

 

 

 

 

“During Q3FY22, we are pleased to share that we have been able to grow our non-covid revenue despite sharp drop in volumes from a government contract. We have made increased investments in digital& marketing, manpower& customer experience initiatives in order to strengthen our brand. This has impacted margins which we believe is a short-term phenomenon.

Our focused cities performance and B2C contribution continues to witness healthy growth and is a testimony to our on-ground efforts and the acceptance of Metropolis Brand in the minds of consumers.

We have also been able to successfully complete the acquisition of Hitech Diagnostics during Q3 which will enable us to scale up our business, improve the B2C revenue contribution and tap the value end of the market.”- Ameera Shah, Promoter and Managing Director, Metropolis Healthcare Ltd.